Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDOXY 200 (doxycycline) by Fresenius Kabi is mechanism of action doxycycline inhibits bacterial protein synthesis by binding to the 30s ribosomal subunit. Approved for infections caused by the following gram-negative microorganisms, infections caused by the following gram-positive microorganisms, 74 percent of enterococcus faecalis (formerly streptococcus faecalis ) have been found to be resistant to tetracycline drugs and 11 more indications. First approved in 1983.
Drug data last refreshed 18h ago
Mechanism of Action Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria.
Worked on DOXY 200 at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Doxycycline vs. Macrolide for MRMP (DOMINO)
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya
A Study of Doxycycline to Treat Chlamydial Infection
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo